Management and coordination of Navarrabiomed's scientific strategy and impact.
Coordination of research and innovation programs.
Promotion of the scientific activity of our research groups by facilitating the development and execution of scientific proposals and programs.
Paula Aldaz Donamaria holds a degree in Health Biology and Biochemistry from the University of Navarra and a Master's degree in Biotechnology and Enterprise from the University of Manchester (UK). She also has extensive training in areas such as European project management, results transfer, and healthcare quality, among others.
In 2017, she obtained her PhD from the University of the Basque Country for her research in the Cellular Oncology group at the IIS Biogipuzkoa. That same year, she joined the Cancer Signaling Unit at Navarrabiomed as a postdoctoral researcher, where she was awarded a Sara Borrell contract from the Carlos III Health Institute.
Throughout her professional career, she has contributed to the development of 20 competitive research projects related to the study of cancer and has contributed to more than 20 scientific articles and two book chapters.
She has also combined her scientific activity with teaching as an associate professor in the Departments of Science and Health Sciences at the Public University of Navarra.
José Arco Martín de Rosales es graduado en Estadística por la Universidad de Granada y Máster en Bioinformática y Bioestadística por la Universitat Oberta de Catalunya. Empezó su carrera profesional en Accenture donde desarrolló tareas de consultor Oracle en varias empresas en Europa, América y España. Posteriormente, se incorporó al Barcelona Supercomputing Center, como Research Engineer, y al Instituto de Investigación del Vall d´Hebron como Clinical Data Project Manager.
Desde febrero de 2025, José Arco ejerce como Responsable del Servicio científico técnico de Biocomputación y Ciencia de datos de Navarrabiomed.
Roberto Hernan is a biologist who completed his PhD researching tumors of the central nervous system at the University of Newcastle upon Tyne (England). During his professional career, he has worked in several private biotechnology companies where he focused on areas such as cancer research, cell cryopreservation or the development of vaccines, among
